bioRxiv Science⌕ Search

Biology subjects

Bednarz, B.

Publications and source records attributed to Bednarz, B..

2 recordsLinked to original sources

The gamma-butyrolactone receptors ScbR and AtrA form a quorum sensing switch between coelimycin and actinorhodin synthesis in Streptomyces coelicolor A3(2)

BackgroundQuorum sensing enables gene expression regulation in response to changes in cell population density and controls diverse processes, such as biofilm formation, virulence and antibiotic production, in bacteria. In one of the largest, soil-dominant phylum Actinobacteria, cell-to-cell communication occurs through the small, membrane-diffusible signalling molecules gamma-butyrolactones (GBLs). Their actions are exerted through receptor proteins that also act as response regulators in a one-component system manner. With only a few GBL systems characterized, most of them come from the large, antibiotic-producer genus Streptomyces. In the model organism Streptomyces coelicolor A3(2), two GBL receptors, ScbR and SlbR, which are both antibiotic production repressors, have been reported so far. ResultsIn this work, we identified a new GBL receptor protein, the conserved and pleiotropic regulator AtrA, which has an activating mode of action. Moreover, we elucidated the precise mechanism by which it controls the production of the antibiotic actinorhodin through the actinorhodin biosynthetic gene cluster activator ActII-orf4. GBL binding to AtrA prevents its binding to the promoter of the actII-orf4 gene, thereby disabling its transcription, while at the same time, GBL binding to ScbR causes coelimycin antibiotic synthesis derepression. ConclusionsThe opposite modes of action of ScbR (repressor) and AtrA (activator) have opposite effects upon GBL binding, activating coelimycin and blocking actinorhodin production at the same time. This phenomenon constitutes an elegant regulatory mechanism that ensures that coelimycin and actinorhodin production are mutually exclusive. These findings also suggest that quorum sensing must be taken into account when designing efficient antibiotic production processes and can be manipulated to ensure both better yield and specificity.

molecular biology↗

Profound immunomodulatory effects of 225Ac-NM600 drive enhanced anti-tumor responsein prostate cancer

An immunosuppressive tumor microenvironment has hampered the efficacy of immunotherapy in prostate cancer. However, radiation-induced immunological effects can partly mediate anti-tumor effects by promoting a pro-inflammatory environment potentially responsive to immunotherapy. Herein, we examined the immunomodulatory properties of a radiopharmaceutical therapy (RPT) with NM600 radiolabeled with either a beta or alpha emitter in two prostate cancer models. 225Ac-NM600, but not 177Lu-NM600, promoted significant anti-tumor effects and improved overall survival. Immunomodulatory effects were dose, radionuclide, and tumor type-dependent. 225Ac-NM600 elicited an array of immunomodulatory effects such as increased CD8/Treg ratio, activation of effector and memory T cells, abrogation of infiltrating suppressor cells (e.g., Tregs and MDSCs), and increased levels of Th1 cytokine and pro-inflammatory chemokines. Importantly, we demonstrate the need to carefully characterize the immune responses elicited by RPT both pre-clinically and clinically to maximize tumor control and avoid potential counterproductive immunosuppressive effects. TeaserTargeted alpha therapy can create a pro-inflammatory tumor micro-environment that partly explains stronger anti-tumor responses in prostate cancer

immunology↗